A Phase I Study of Oblimersen (Genasense, G3139) in Combination With Gemcitabine in Advanced Malignancies
Phase of Trial: Phase I
Latest Information Update: 24 Jan 2013
At a glance
- Drugs Oblimersen (Primary) ; Gemcitabine
- Indications Lymphoma; Solid tumours
- Focus Adverse reactions
- 08 Apr 2009 Actual end date (November 2003) added as reported by ClinicalTrials.gov.
- 13 Aug 2008 Status changed from suspended to in progress as reported by ClinicalTrials.gov.
- 17 Aug 2005 New trial record.